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The European Network for Diagnostics of “Imported” Viral Diseases 
(ENIVD) is finalising a project to improve the diagnostic and 
monitoring of encephalitis viruses in Europe. Part of this study 
was to analyse the present surveillance situation for tick-borne 
encephalitis (TBE), which is the most important flavivirus infection 
of the central nervous system in the European Union (EU) and 
Russia. A questionnaire was mailed to contact points in all Member 
States of the EU and three non-EU countries (Norway, Russia and 
Switzerland) to summarise their TBE surveillance and prevention 
activities. Information was requested on case definition, type 
of laboratory tests for TBE diagnostics, investigations regarding 
tick-transmitted diseases, mapping of endemic foci, vaccination 
programmes, and recommendations for travellers. The survey gives 
an overview of the existing epidemiological and laboratory sources 
of information and the number of TBE cases from 2004 until 2007, 
but also showed that, in particular, case definitions, diagnostic 
assays for confirmation, and methods/indicators for mapping risk 
areas differ widely across the participating countries. The data 
will help to develop recommendations for the standardisation and 
quality control of TBE surveillance and diagnostics. 
Introduction
Tick-borne encephalitis (TBE) is the most important flavivirus 
infection of the central nervous system (CNS) in Europe and Russia. 
The total annual number of cases is estimated to be up to 10,000 
in Russia and about 3,000 in European countries [1-4]. According 
to the International Committee for Taxonomy of Viruses, TBE virus is 
classified as one species with three subtypes, namely the European 
subtype (which comprises almost all known isolates from Europe), 
the Siberian subtype (mainly isolates from Urals, Siberia and far-
eastern Russia) and the Far Eastern subtype (mainly isolates from 
far-eastern Russia, China and Japan).
The three TBE virus subtypes are associated with varying degrees 
of disease severity [2-4]. Human infections with Far Eastern 
subtype viruses are usually severe, frequently with encephalitic 
symptoms (focal meningoencephalitis or polyencephalitis), with 
an associated fatality rate between 5 and 35%. This type does 
not cause chronic disease. In contrast, TBE virus infections of the 
Siberian subtype cause a less severe disease (fatality rate between 
1 and 3%), with a tendency for patients to develop chronic or 
extremely prolonged infections accompanied by diverse neurological 
and/or neuropsychiatric symptoms. In contrast to these two forms, 
infections caused by European strains typically take a biphasic 
course [5]: after a short incubation period (usually 7–14 days, 
with extremes of 4–28 days), the first (viraemic) phase presents as 
an uncharacteristic influenza-like illness lasting 2–4 days (range 
1–8 days) with fever, malaise, headache, myalgia, gastrointestinal 
symptoms, leukocytopenia, thrombocytopenia and elevated liver 
enzymes, often followed by a symptom-free interval of about 
one week (range 1–33 days). The second phase of TBE occurs 
in 20–30% of infected patients and is marked by four clinical 
features of different severity (meningitis, meningoencephalitis, 
meningoencephalomyelitis or meningoencephalo-radiculitis) and the 
appearance of specific antibodies in the serum and cerebrospinal 
fluid (CSF). This is usually the time when patients with high fever 
and severe headache seek medical advice. The fatality rate in adult 
patients is less than 2%. However, severe courses of TBE infection 
with higher mortality and long-lasting sequelae often affecting 
the patient’s quality of life have been correlated with increased 
age [6-8]. More detailed information on the clinical picture, case 
definition and other issues of interest are available in a TBE fact 
sheet on the ENIVD website [http://www.enivd.org].
The epidemiology of TBE is closely related to the ecology and 
biology of ticks [2,3,9,10]. In nature, TBE virus is propagated in 
a cycle involving permanently infected ticks and wild vertebrate 
hosts. Virus transmission occurs horizontally between tick vectors 
and vertebrates, especially between spring and autumn, with small 
mammals (mainly rodents) serving as virus reservoirs. In addition, 
trans-stadial and trans-ovarial transmission of the virus, as well 
as co-feeding of infected and non-infected ticks on the same 
host play a major role in virus transmission [11]. In contrast to 
other tick-transmitted diseases, such as Lyme borreliosis, TBE is 
distributed in an endemic pattern of so-called natural foci over 
a wide geographical area focussed on central Europe, the Baltic 
states and Russia. The distribution of TBE is determined by the 
occurrence of the respective tick vectors in certain regions [3,10]. 
While Ixodes ricinus is the prevalent hard tick species across Europe 
and therefore the most important transmitter of the European TBE 
virus subtype, Ixodes persulcatus occurs in forest regions of the 
Urals, Siberia and far-eastern Russia and is the main vector of the 
other subtypes. Co-circulation of two or all three subtypes could 
be shown for Finland and the Baltic states where the distribution 
areas of the two main tick species overlap [12,13]. 
However, the virus prevalence in ticks as well as the prevalence of 
infected ticks within the risk areas can vary [4,9,14,15]. Countries 
with high-risk areas are Russia, Latvia, Lithuania and Estonia. TBE 
is also a significant issue in Germany, the Czech Republic, Poland, 
Switzerland, Sweden, Finland, Slovakia, Hungary and Slovenia. 
Even in Austria, the only country with progressively decreasing 
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incidences since 1981 (due to high vaccination coverage [16]), 
the occurrence of TBE may be of relevance for unvaccinated 
tourists. In France, Italy, Greece, Norway and Denmark, TBE is 
of minor importance. In the United Kingdom, Ireland, Belgium, 
the Netherlands, Luxembourg, Spain and Portugal, TBE is not 
indigenous. Detailed epidemiological statistics from 1990 onwards 
can be obtained from the website of the International Scientific 
Working Group on TBE [http://www.isw-tbe.info]. 
An increase of TBE incidence has been observed in the risk 
areas (both high- and low-risk) in some of the endemic countries 
mentioned above, especially in the last decade [15,17-20]. In 
addition, new TBE foci have appeared in Europe. This is due to a 
complex interrelation of several factors, such as social (e.g. socio-
political changes, human leisure activities), ecological (e.g. effects 
of climate changes on vectors) and/or technological factors (e.g. 
advanced diagnostics and increased medical awareness) [20-24]. 
The collection of epidemiological data is indispensable in order 
to predict endemic foci and to recommend preventive measures. 
Several methods can be employed to investigate the epidemiological 
situation of TBE [10]:
1. examination of ticks and animal reservoirs for the presence of 
TBE virus (especially by molecular diagnostic techniques); 
2. seroprevalence study of people exposed to ticks; and 
3. describing clinical cases and their geographical location. 
TBE is a growing concern in Europe, but the surveillance and 
notification schemes are not uniform and not always mandatory 
and may affect the prevalence estimates for the disease in certain 
regions [25,26]. Main problems are the lack of a Europe-wide 
standard case definition, wide differences in the quality of national 
surveillance of TBE cases, and varying diagnostic procedures. Thus, 
surveillance data from different countries are difficult to compare. 
Furthermore, little is known about the true TBE virus prevalence 
in tick populations or about the circulation of new subtypes in 
Europe. 
Currently, the European Network for Diagnostics of “Imported” 
Viral Diseases (ENIVD) is finalising a project to improve the 
diagnostic and monitoring of encephalitis viruses in Europe. Its tasks 
are being defined in several working groups [27]. Here, the ENIVD-
working group for TBE virus describes the results of a questionnaire 
survey on the present TBE surveillance situation in Europe, which 
will help to develop recommendations for the standardisation and 
quality control in TBE surveillance and diagnostics. 
Methods
To request information on TBE surveillance and prevention 
activities in national surveillance systems, a questionnaire with 
10 questions was mailed to contact points in all member states 
of the European Union (EU) and three non-EU countries (Norway, 
Russia and Switzerland) based on an ENIVD database of expert 
microbiologists and epidemiologists. The questions were the 
following:
1. Is TBE a notifiable disease in your country? (Since when?)
2. Is there an official reference base to which the annual number 
of cases is reported?
3. Does a clear case definition for TBE exist? (If yes, what is it?)
4. What kind of diagnostic assays are used most often to diagnose 
TBE?
5. Is there an expert or reference laboratory for TBE infections in 
your country? (If yes, what are their contact details?)
6. What was the annual number of human cases between 2004 
and 2007?
7. Are there any regular investigations regarding tick-transmitted 
diseases? (If yes, what kind of investigations?) 
8. Do you map endemic foci/risk areas? (If yes, based on what 
kind of data?)
9. Is there an official vaccination programme for TBE in your 
country?
10. Are there official recommendations regarding TBE vaccination 
for travellers to TBE endemic areas?
Results 
Of 30 contacted countries, 19 EU member states and three 
non-EU countries (Norway, Russia and Switzerland) participated in 
this survey (recovery rate: 73%) (Figure 1). All contributors are listed 
in the acknowledgements section. The completed questionnaires 
were returned during the summer trimester of 2007. The TBE case 
numbers for 2007 were added afterwards in February/March 2008. 
Therefore, the results of this survey reflect national surveillance 
systems and case numbers for TBE up to these dates.
F i g u r e  1
Form of notification for tick-borne encephalitis in Europe 
and Russia (survey participants)
Specific tick-borne encephalitis notification
Non-notifiable disease or non-specific notification
Country did not participate in the  survey
T a b l e  1
Survey data regarding surveillance systems on tick-borne encephalitis in European countries* 













Austria Yes1) Serological proven hospitalised TBE cases are counted ELISA
Survey on TBE and 
borreliosis For human cases Yes Yes






for human cases, 







Clinical and laboratory signs of aseptic 
meningitis/ meningoencephalitis and positive 
TBE virus serology
Mostly ELISA, 
in NRL for 
arboviruses: CFT 
and VNT
Tick surveillance in 
natural foci (TBE and 
borreliosis) 
For human cases and 
infected ticks No (optional) Not known
Estonia Yes, since 1970
Possible case: typical clinical case history 
(biphasic course of infection), epidemiological 
links (e.g. tick bite); Confirmed case: with 
laboratory confirmation: not less than four-fold 
increase in antibody titre in pair-sera or IgM-
antibodies in serum/CSF or positive PCR5)
IFA, ELISA, VNT, 
PCR, SEQ, 
VI, WB, HIA
Survey on TBE For human cases No (optional) Yes
Finland Yes, since 1996
TBE virus-IgM positive with suitable clinical 




and HIA (PCR 
only for tick 
studies)
Tick field surveys (TBE, 
babesia and anaplasma) For human cases





For the diagnosis of TBE, a double check on a 
pair of serum samples is required (not further 
specified)
ELISA, VNT only 
in very few 
cases (PCR not 
in routine)
Survey on patients with 
risk of exposure in 
infested areas as well 
as outside
For human cases 
(only Alsace region) No (optional) No
Germany Yes, since 2001
Clinical CNS symptomatic case with positive 
PCR in blood/CSF or IgM- and IgG-antibodies in 
blood/CSF or increase in IgG-antibody titre or 
intrathecal antibody production7)
ELISA
Tick surveillance (TBE); 
surveys on borreliosis 
and rickettsiosis 
For human cases Yes Yes
Greece Yes2)
Clinical CNS symptomatic case with: positive 
PCR in clinical sample, increased IgG and IgM 




Survey on TBE (human 
cases, serosurvey, ticks); 
survey on CCHF and on 
bacterial tick-borne 
diseases
For human cases and 
ticks, in northern 
Greece
No (optional) Yes, if requested
Hungary Yes since 1977
Aseptic meningitis, encephalitis or 
meningoencephalomyelitis confirmed by 
laboratory tests
IFA, HIA, ELISA
Regular: human cases, 
serosurvey (TBE); project 
on tick survey (until 
2008)
For human cases and 
TBE natural foci













Latvia Yes, since 1999 No ELISA
Survey on TBE and 
borreliosis; tick survey






Lithuania Yes, since 1969
Officially no, but reported cases are 
serologically proven hospitalised TBE cases ELISA Annual tick activity For human cases No (optional) Yes
Poland Yes, since 1970
Clinical description: typical clinical case 
history (biphasic course of infection); 
Laboratory criteria: demonstration of four-fold 
or greater rise of antibody titre in serum or 
demonstration of intrathecal antibodies or 
virus isolation from tissues, blood or CSF (for 
probable case: demonstration of IgM antibodies 
in serum with no history of previous flaviviral 
exposition); classification in possible, probable 
or confirmed cases8)







Portugal No No IFA
Survey on rickettsia, 
borrelia and 
arboviruses; tick survey
No No (optional) No
Slovakia Yes, since 1950 Not known
ELISA, HIA (PCR 
in specific 
cases)
Survey on TBE and tick 
survey No No (optional) Yes
Slovenia Yes, since 1977
A case of TBE is considered to be confirmed by 
the following findings: fever, clinical signs/
symptoms of meningitis or meningoencephalitis, 
an elevated CSF cell count (>5x105
cells/L), and serum IgM anti-bodies to TBE virus 
and/or IgG seroconversion
ELISA, PCR
Survey on human cases 





For human cases, 
ticks and reservoirs Yes Yes




Under discussion, but reported cases are based 
on clinical picture and positive serology ELISA No
Human cases, 
incidence No (optional) No
The 
Netherlands No No ELISA, PCR
Survey on borreliosis 
(RIVM, Bilthoven) For borellia No (optional) No
Norway Yes, since 1975 No ELISA
Survey on borreliosis 
For human cases, 
serosurvey in 
dogs (areas of 
Kristiansand)
No (optional) No
Russia Yes, since 1950 No formal case definition ELISA
Survey on human cases 
and in ticks forTBE, 
orreliosis, rickettsiosis, 
CCHF







Switzerland Yes, since 2001 Not known ELISA No







* Data provided by listed contributors.
1) Notified if meningoencephalitis. Start of notification not further specified. 
2) Notification as arboviral encephalitis since 2002 as part of the Commission decision 2002/253/EC.  
3) Notification of all acute viral encephalitis cases since 1990. Not specifically TBE.
4) Notifiable 1969-1989, and again from July 2004. Voluntary reporting during the period 1990 - June 2004.
5) Case definition used since 2004.
6) A Baltic/Nordic working group on TBE started  in October 2007 to discuss  an appropriate case definition.
7) Case definition of the Robert Koch Institute according to the Law for the Prevention of Infections (Infektionsschutzgesetz, IfSG), 2007 
8) Case definition used since January 2005.
CFT: complement fixation test; CSF: cerebrospinal fluid; ELISA: enzyme linked immunosorbent assay; HIA: haemagglutination inhibition assay; IFA: immunofluorescence assay; 
PCR: polymerase chain reaction; SEQ: sequencing; VI: virus isolation; VNT: virus neutralisation; WB: Western blot. CCHF: Crimean Congo haemorrhagic fever; TBE: tick-borne 
encephalitis. NRL: National reference laboratory 
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Case reporting
While TBE cases were specifically notifiable in 16 of the 22 
participating countries (73%), at the time of the survey, notification 
of TBE was not mandatory in Belgium, France, Italy, Portugal, 
Spain and the Netherlands (Figure 1). Of the 16 countries with 
TBE notification, eight (Austria, Czech Republic, Germany, Greece, 
Hungary, Poland, Slovenia and Sweden) had a case definition based 
on clinical criteria and laboratory confirmation, two (Estonia and 
Finland) also included cases with an epidemiological link (e.g. tick 
bite), and the remaining six countries (Latvia, Lithuania, Norway, 
Russia, Slovakia, and Switzerland) had no officially or clearly 
formulated case definition (Table 1). From Finland and Sweden 
we know, that the present case definitions are under discussion 
and will soon be harmonised among the Baltic and Nordic states 
(the discussion started in October 2007 and is planned to be done 
by June 2008). 
Although clear case definitions were provided by ten countries, 
differences could be seen in the classification of relevant 
TBE cases as aseptic meningitis, meningoencephalitis and/or 
meningoencephalomyelitis (see e.g. classifications in Austria, 
Czech Republic, Hungary or Slovenia), as well as in the application 
of laboratory tests for case confirmation (Table 1). Commonly, the 
routine laboratory diagnosis of TBE is based on the detection 
of specific antibodies by enzyme linked immunosorbent assay 
(ELISA) as done in 20 participating countries (91%). Polymerase 
chain reaction (PCR) is included for particular investigations (e.g. 
tick studies or severe cases) by 10 countries (45%); followed by 
other methods like immunofluorescence assay in five countries; 
haemagglutination assay and virus neutralisation tests in four 
countries, respectively; and virus isolation in three countries. Other 
less common methods like complement fixation test, sequencing 
and Western blot are used in the Czech Republic and Estonia.
Surveillance activities
While for Italy, Sweden and Switzerland information on 
further investigations regarding tick-transmitted diseases (e.g. 
TBE, borreliosis, babesiosis, ehrlichiosis, rickettsiosis) were not 
available, the other 19 countries could provide these data (Table 
1). They conduct mainly human serosurvey studies on borreliosis 
or TBE (10 countries each), followed by surveys on rickettsiosis 
in five countries. Surveys on the prevalence of TBE virus in tick 
populations were also performed in seven countries; for anaplasma 
(the causative agent of ehrlichiosis in Europe) and borrelia in four 
countries, and for babesia, rickettsia and other relevant pathogens 
in three countries, respectively. All countries except Portugal, 
Slovakia and Spain provided information on what kind of data 
they based their TBE risk assessments on (Table 1). The mapping 
of risk areas is mainly based on the geographical incidence of 
autochthonous clinical cases (18 countries), while seven countries 
also included data on infected ticks in the risk assessment, and 
only four countries used data from natural reservoirs (e.g. rodents) 
or indicator hosts (e.g. roe deer, dogs). The Netherlands used this 
kind of data only for risk assessment of borreliosis. 
Trends in TBE incidence
Based on the data from this survey we are able to present an 
overview of the TBE situation in 14 European countries from 
2004 until 2007 (Figure 2). Other participating countries have 
provided no (Belgium, Greece, Italy, Portugal, Spain) or only few 
data (France, The Netherlands, Norway).
F i g u r e  2
Annual case numbers and incidences (per 100,000 
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For the presented period of the past four years certain tendencies/
changes in the TBE incidence can be extracted. Following clear 
increases of the annual case numbers in 2004-2006 (approximately 
two-fold) in the Czech Republic (with more than 1,000 cases in 
2006, the highest reported number since notification began), 
Germany (with an all-time high of 546 cases in 2006), Slovenia 
(with 373 cases in 2006, the highest number since 1994) and 
Switzerland (with the highest number, 244 cases, in 2006) the 
incidences in these countries declined in 2007. A similar trend in 
annual TBE case numbers could be observed for Austria. However, 
T a b l e  2
Survey data regarding surveillance systems on tick-borne encephalitis in European countries*
Member 





(Institute of Virology, Medical University of Vienna)
Univ.-Prof. Dr. F. X. Heinz
Institute of Virology, Medical University of Vienna
Belgium http://www.iph.fgov.be/epidemio/epien/index0000.htm(Scientific Institute of Public Health, Brussels)
Dr. P. Heyman





(National Institute of Public Health, Prague)
Prim. Dr. J. Januška
NRL for arboviruses, National Institute of Public Health, Ostrava
Estonia http://www.tervisekaitse.ee/(Health Protection Inspectorate, Tallinn)
Dr. I. Golovljova
National Institute for Health Development, Tallinn
Finland http://www3.ktl.fi(National Public Health Institute, Helsinki )
Prof. O. Vapalahti
Haartman Institute, University of Helsinki
France http://www.pasteur.fr/sante/clre/cadrecnr/arboFHV-index.html(National Reference Centre for Arboviruses, Lyon)
Dr. H. Zeller
Unit for the biology of emerging viral infectious (UBIVE) Institut 
Pasteur, Lyon
Germany http://www.rki.de/DE/Content/Infekt/EpidBull/epid__bull__node.html(Robert Koch-Institute, Berlin)
Prof. J. Süss
NRL on tick-borne pathogens, Friedrich-Löffler-Institute, Jena
Greece http://www.keel.org.gr/(Hellenic Centre for Infectious Disease Control, Athens)
Prof. A. Papa 
School of Medicine, Aristotle University of Thessaloniki
Hungary Yearbook of Health Statistics(National Centre for Epidemiology, Budapest)
Dr. E. Ferenczi
NRL for viral zoonoses, National Center for Epidemiology, Budapest
Italy not provided
Dr. L. Nicoletti
Arbovirus Laboratory, Italian National Institute of Health,(Istituto 
Superiore di Sanitá), Rome
Latvia http://www.sva.lv/epidemiologija/statistika/(State Public Health Agency, Riga)
Dr. T. Kolupajeva
Infectology Centre of Latvia, Riga
Lithuania http://www.ulpkc.lt(Centre for Communicable Disease Prevention and Control, Vilnius)
Dr. A. Griskevicius
Lithuanian AIDS centre laboratory, Vilnius
Netherlands not provided
Dept. of Virology, Unit Diagnostics, Erasmus MC, Rotterdam and 
Laboratory of Virology, National Institute for Public Health and the 
Environment (RIVM), Bilthoven
Poland http://www.pzh.gov.pl/epimeld/index_a.html(National Institute of Hygiene, Warsaw)
Associate Professor B. Litwińska
NRL for arboviruses, National Institute of Hygiene, Warsaw 
Portugal not provided
Dr M.T. Paixão
Centre for Vectors and Infectious Diseases Research (CEVDI) National 
Institute of Health, Lisboa
Slovakia Regional Public Health Authority, Banska Bystrica
Ing. Z. Sirotná
NRC for arboviruses, Public Health Authority of the Slovak Republic, 
Bratislava
Slovenia http://www.ivz.si/ (Institute of Public Health Republic of Slovenia, Ljubljana)
Prof. Dr. T. Avšič-Županc
Instituteof Microbiology and Immunology, University of Ljubljana
Spain http://cne.isciii.es(National Centre of Epidemiology, Institute of Health Carlos III, Madrid)
Dr. A. Tenorio
CNM Institute of Health Carlos III, Majadahonda-Madrid
Sweden Annual report of the Department of Epidemiology, Swedish Institute for Infectious Disease Control
Swedish Institute for Infectious Disease Control, SE 171 82 Solna, 
Sweden 
Norway http://www.msis.no/emsisexternalweb/Forside.htm#_Welcome_to_the(Norwegian Institute of Public Health, Oslo) not provided
Russia
Annual (or biannual) Book “Infectious morbidity in the provinces of 
Russian Federation”
(Federal Centre of Hygiene and Epidemiology, Moscow)
Dr. A.E. Platonov




(Federal Office of Public Health, Bern)
Dr. D. Schultze
Institute for Clinical Microbiology (IKMI), St. Gallen
* Data provided by listed contributors.
† Further contact information can be provided on request.
NRL: National Reference Laboratory; NRC: National Reference Centre 
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the incidence in Slovenia changed dramatically from 10.2 cases 
per 100,000 inhabitants in 2004 to 18.6 cases per 100,000 in 
2006, and is now similar to incidences in Lithuania and Estonia, 
countries that are usually among the countries with the highest 
incidence rates. In Latvia, the incidence has decreased significantly 
in 2005 and since remained stable with approximately seven cases 
per 100,000 inhabitants. Among the Nordic countries, Sweden had 
the highest incidences with a gradual increase from 127 cases in 
2005 to 189 cases in 2007. While Lithuania, Poland and Slovakia 
showed considerable fluctuations in the annual TBE case numbers, 
the trends in the remaining countries were more or less stable. 
However, we found high incidence levels in the Czech Republic, 
Estonia, Latvia, Lithuania and Slovenia in 2007 (5.3-13.2), 
considerable incidence levels for Slovakia, Sweden, Russia and 
Switzerland (1.0-2.2), and incidence levels under 1.0 cases per 
100,000 inhabitants for Austria, Finland, Germany, Hungary and 
Poland. The epidemiological and laboratory sources of information 
for the TBE surveillance data are listed in Table 2.
Vaccination policy
Only in Austria, Finland, Germany, Hungary, Latvia, Slovenia, 
Russia and Switzerland, TBE vaccination is included in an official 
governmental vaccination programme under certain conditions. In 
the remaining 14 countries, it is available as an optional vaccination, 
partly recommended, but not reimbursed by health insurance 
companies (Table 1). In Austria (with a successful vaccination 
campaign since 1981), Germany and Switzerland, health insurance 
companies cover the vaccination costs for people who are at risk of 
exposure to ticks in risk areas [28-30]. In Finland, TBE vaccination 
has been offered for free since 2006 only for the Ǻland islands 
which have the highest incidence rate of the country. Hungary has 
a programme only for people at occupational risk. Also in Slovenia, 
vaccination is only obligatory for forest workers, farmers, military 
personnel and other occupationally exposed people. In Latvia, a 
free vaccination programme was started for children from regions 
with high incidences in March 2007. TBE vaccination in Russia is 
recommended, but currently not financed by federal budget. There 
are some programmes on regional level based on province budget 
or other financial sources. 
Travel recommendations
Austria, Belgium, Estonia, Finland, Germany, Greece, Latvia, 
Lithuania, Poland, Slovakia, Slovenia, Spain and Switzerland stated 
that they had more or less official recommendations regarding TBE 
vaccination for people travelling to endemic areas, the other nine 
participating countries did not provide information on this issue 
(Table 1). Although the responses to this part of the questionnaire 
suggested that the contact points had not interpreted the question 
in the same way, it can be deduced that information for travellers 
is given for following purposes:
a) General information included in national vaccination programmes 
for citizens coming from non-endemic regions (e.g. in Austria 
and Poland);
b) Information on the endemic status of a country for citizens and 
visitors (limited information in the Baltic states, Slovakia and 
Slovenia, and comprehensive information in Finland, Germany 
and Switzerland); 
c) Information on the endemic status of foreign countries for 
citizens travelling abroad (e.g. in Belgium and Spain).
Discussion
TBE is an emerging disease which occurs and spreads among 
central and western European countries, Scandinavia, countries 
from the former Soviet Union, and Asia where it has a significant 
impact on public health. The epidemiology of TBE is very complex, 
and closely related to the distribution of ixodid ticks. Based on this 
survey which comprises updated information on TBE surveillance 
in Europe since the last overview published in 2004 [31], TBE is 
a notifiable disease, namely in Austria, the Baltic states, Czech 
Republic, Finland, Germany, Greece, Hungary, Norway, Poland, 
Russia, Slovakia, Slovenia, Sweden and Switzerland. 
While we were able to present an overview of the TBE situation 
in 14 European countries (based on annual case numbers from 
2004 to 2007) in which the disease poses a major threat to public 
health, other participating countries provided no or only very few 
data for this survey. A reason for this could be that TBE is not 
indigenous or a disease of minor importance in these countries. 
However, single cases of TBE have been documented in France 
in the Alsace region and more recently in Bordeaux [32], in the 
northern as well as central part of Italy [1], in northern Greece [33], 
and also in Norway (southern coast area) and Denmark (Bornholm) 
[34]. Unfortunately, details about the TBE annual case numbers 
in Romania and other eastern European countries could not be 
obtained and remain unclear.
To understand the described tendencies and changes in the TBE 
incidence during the past four-year-period as well as the fluctuation 
in incidence rates observed particularly during the last decade 
among European countries, a complex interrelation of several 
factors has to be considered, such as social, ecological and/or 
technological factors [15, 17-24]. It seems more appropriate to 
base a discussion of the TBE epidemiology on these factors – the 
importance of which can vary depending on the country – rather 
than on climate change alone. In particular, due to the mild winter 
in 2006/2007, it was not to be expected that the TBE incidences 
would decline in 2007 for Austria, the Czech Republic, Germany, 
Slovenia and Switzerland. Similar observations have been discussed 
in previous publications regarding the increase of incidence and 
appearance of new foci, for example in Nordic and Baltic states 
[24,35]. Thus changes of leisure activities in nature, increasing/
decreasing mobility to risk areas, changes in wildlife hosts/tick 
populations, improved diagnostics or vaccination campaigns may 
have influenced the quantity and quality of epidemiological data. 
In the case of Latvia, the observed decrease in incidence from 
approximately 11 cases per 100,000 inhabitants in 2004 to seven 
cases per 100,000 in 2005 and the following years, probably 
reflects the initiation of vaccination activities [36]. 
Knowledge about endemic foci needs to be expanded (also in 
countries where TBE is of minor importance) and regularly updated 
in order to identify the risk for the exposed population and to apply 
TBE vaccines in an optimal way. For an appropriate collection of 
epidemiological data, a broad standard case definition including 
all possible clinical signs of laboratory-confirmed TBE should be 
used in European countries in order to avoid under-ascertainment 
of cases and to increase the knowledge on the true incidence of 
TBE [25,26].
Currently, the routine laboratory diagnosis of TBE is based 
mainly on the detection of specific antibodies in serum and 
CSF, usually by ELISA. However, certain limitations need to be 
taken into consideration when using serological methods [37]: 
An early diagnosis by detecting only IgM is questionable, since 
IgM antibodies can persist for up to 10 months in vaccinees 
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or individuals who acquired the infection naturally. Therefore, 
confirmation by detection of specific IgG is recommended, but 
may turn out negative in the first phase of infection. Although it is 
necessary to monitor IgG titres one or two weeks later for a possible 
increase, this is rarely done. Moreover, a major problem when using 
ELISA and IFA are cross-reactions of antibodies induced by other 
flavivirus infections or vaccinations (e.g. Dengue virus, West Nile 
virus, Yellow fever virus and Japanese encephalitis virus). It is 
therefore advised to verify positive results by neutralisation test. Due 
to the use of infectious virus particles, this requires the handling 
in biosafety level 3 facilities, making the test time-consuming, 
expensive and only available in highly specialised laboratories. 
PCR techniques have also been developed in a remarkable way 
lately and new publications reveal that RT-PCR methods can be 
of great diagnostic value in the early diagnosis of TBE and in 
the discrimination among virus subtypes [37]. However, they are 
mainly restricted to the first phase of infection. Serological and/or 
molecular testing should be performed using standard operation 
protocols (SOPs) among European countries and should be regularly 
monitored by external quality assurance programmes to guarantee 
the comparability of data from clinical diagnosis, epidemiological 
surveillance and surveys on the incidence of TBE virus in ticks and 
vertebrate hosts [38]. 
While Lyme borreliosis, another tick-transmitted disease of 
similar epidemiological importance in Europe, can be treated 
with antibiotics, no specific treatment for TBE is available to 
date and the administration of TBE immunoglobulin for a passive 
post-exposure prophylaxis is highly questionable [39] and not 
recommended anymore for example in Germany. The last application 
was discontinued many years ago as the preparations for passive 
immunisation are no longer produced. 
Due to the fact that TBE causes high costs for health care 
systems (intensive care in hospitals, possible long-lasting cognitive 
and neuropsychiatric sequelae etc.) TBE vaccination should be 
recommended and reimbursed for residents of and travellers to 
TBE endemic areas, who are at risk of tick bites. The Austrian 
example shows that systematically increased vaccination coverage 
will result in the decrease of morbidity and therefore hospitalised 
cases [16]. A further important question of great public health 
impact, not addressed in this survey, is the diagnosis of vaccine 
failure [25]. The protective efficacy of the widely used TBE vaccines 
cannot be properly evaluated if no quality assurance exists for the 
diagnosis of vaccine failures. Since this is a difficult procedure, 
the question arises of whether national reference laboratories on 
CNS diseases should handle the relevant tests and establish widely 
accepted criteria on how to define a vaccine failure. Furthermore, 
since awareness among tourists as well as consulting doctors is 
rather rare [22] recommendations for travellers should be provided 
by state institutions regardless of whether these institutions are in 
countries with endemic (e.g. Germany) or non-endemic (e.g. Spain) 
situation. These can be done using country-specific risk profiles 
based on the epidemiological data. Today, existing risk maps on this 
issue are mainly distributed through the vaccine manufacturers. 
Bringing national data on incidences and prevalence together and 
distributing such maps may therefore be an important role for a 
European public health institution.
The participating countries mainly applied the surveillance data 
from clinical cases as an indicator for predicting endemic foci 
and for recommending preventive measures. Due to the fact that 
incidences of human cases may decrease in future because of mass 
vaccination programmes, alternative indicators for risk assessment 
are necessary. Therefore, the intro-duction of tick or animal reservoir 
surveys for prevalence studies of TBE virus have a high priority and 
should be implemented in national surveillance systems as initiated 
in previous studies [40-42] . So far, methods for measuring virus 
prevalence in ticks or animal reservoirs have not been standardised, 
and reliable tools should be introduced to translate epizootic 
prevalence data into infection risk for humans.
The implementation of the recommendations given in this report 
could be helpful, to gain more valuable clinical and epidemiological 
data on TBE, to improve national surveillance systems and to 
reduce the incidence rate for the most important flavivirus CNS 
infection in Europe. 
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